Evidence map›Paper›PMID 32478867›Full record

ReviewCancer2020

Management of primary skin cancer during a pandemic: Multidisciplinary recommendations.

Brian C Baumann, Kelly M MacArthur, Jerry D Brewer, William M Mendenhall, Christopher A Barker, Jeremy R Etzkorn, Nathaniel J Jellinek, Jeffrey F Scott, Hiram A Gay, John C Baumann and 8 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Is cancer a prognostic factor for severe COVID-19, especially for breast cancer patients?Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2022
    Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Brian C BaumannDepartment of Radiation Oncology, Washington University in St. Louis, St. Louis, Missouri, USA.ORCID 0000-0002-7482-1413
Kelly M MacArthurDivision of Dermatologic Surgery, Washington University in St. Louis, St. Louis, Missouri, USA.
Jerry D BrewerDivision of Dermatologic Surgery, Mayo Clinic, Rochester, Minnesota, USA.
William M MendenhallDepartment of Radiation Oncology, University of Florida at Gainesville, Gainesville, Florida, USA.ORCID 0000-0002-6592-2810
Christopher A BarkerDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jeremy R EtzkornDivision of Dermatologic Surgery, Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Nathaniel J JellinekDermatology Professionals Inc, East Greenwich, Rhode Island, USA.
Jeffrey F ScottDivision of Dermatologic Surgery, Department of Dermatology, Johns Hopkins University, Baltimore, Maryland, USA.
Hiram A GayDepartment of Radiation Oncology, Washington University in St. Louis, St. Louis, Missouri, USA.
John C BaumannPrinceton Radiation Oncology, Princeton, New Jersey, USA.
Farrin A ManianDepartment of Internal Medicine, Massachusetts General Hospital, Harvard University, Boston, Massachusetts, USA.
Phillip M DevlinDepartment of Radiation Oncology, Brigham and Women's Hospital, Harvard University, Boston, Massachusetts, USA.
Jeff M MichalskiDepartment of Radiation Oncology, Washington University in St. Louis, St. Louis, Missouri, USA.
Nancy Y LeeDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Wade L ThorstadDepartment of Radiation Oncology, Washington University in St. Louis, St. Louis, Missouri, USA.
Lynn D WilsonDepartment of Therapeutic Radiology, Yale University, New Haven, Connecticut, USA.
Carlos A PerezDepartment of Radiation Oncology, Washington University in St. Louis, St. Louis, Missouri, USA.
Christopher J MillerDivision of Dermatologic Surgery, Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the coronavirus disease 2019 (COVID-19) pandemic, providers and patients must engage in shared decision making regarding the pros and cons of early versus delayed interventions for localized skin cancer. Patients at highest risk of COVID-19 complications are older; are immunosuppressed; and have diabetes, cancer, or cardiopulmonary disease, with multiple comorbidities associated with worse outcomes. Physicians must weigh the patient's risk of COVID-19 complications in the event of exposure against the risk of worse oncologic outcomes from delaying cancer therapy. Herein, the authors have summarized current data regarding the risk of COVID-19 complications and mortality based on age and comorbidities and have reviewed the literature assessing how treatment delays affect oncologic outcomes. They also have provided multidisciplinary recommendations regarding the timing of local therapy for early-stage skin cancers during this pandemic with input from experts at 11 different institutions. For patients with Merkel cell carcinoma, the authors recommend prioritizing treatment, but a short delay can be considered for patients with favorable T1 disease who are at higher risk of COVID-19 complications. For patients with melanoma, the authors recommend delaying the treatment of patients with T0 to T1 disease for 3 months if there is no macroscopic residual disease at the time of biopsy. Treatment of tumors ≥T2 can be delayed for 3 months if the biopsy margins are negative. For patients with cutaneous squamous cell carcinoma, those with Brigham and Women's Hospital T1 to T2a disease can have their treatment delayed for 2 to 3 months unless there is rapid growth, symptomatic lesions, or the patient is immunocompromised. The treatment of tumors ≥T2b should be prioritized, but a 1-month to 2-month delay is unlikely to worsen disease-specific mortality. For patients with squamous cell carcinoma in situ and basal cell carcinoma, treatment can be deferred for 3 months unless the individual is highly symptomatic.

Indexed as

BetacoronavirusClinical Decision-MakingComorbidityCoronavirus InfectionsCOVID-19HumansImmunocompromised HostMorbidityPandemicsPhysiciansPneumonia, ViralSARS-CoV-2Skin NeoplasmsTime-to-Treatmentbasal cell carcinomacoronavirus disease 2019 (COVID-19)cutaneous squamous cell carcinomamelanomaMerkel cell carcinomaMohs surgeryradiotherapyskin cancertreatment delays

Identifiers

PMID32478867
PMCPMC7301000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.